Pharma Two B announced a poster presentation of integrated safety and efficacy data on P2B001 from its Phase 2b and Phase 3 studies in early-stage Parkinson’s disease patients. P2B001 is a fixed ...
Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson's disease (PD) support P2B001 as a first line, once-daily treatment choice for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback